Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IPA | US
-0.00
-0.89%
Healthcare
Biotechnology
31/07/2024
21/10/2024
0.54
0.55
0.55
0.51
ImmunoPrecise Antibodies Ltd. together with its subsidiaries engages in antibody production and provision of related services in the United States Canada Europe Australia and internationally. The company offers a range of antibodies enzymes enzyme activity assays arthritis animal products proteins deiminated proteins organoid growth factors and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling design and manufacturing; B cell sorting screening and sequencing; custom immune and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific tri-specific VHH and VNAR (shark) antibody manufacturing; DNA cloning protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed high-throughput screening and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria Canada.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.3%1 month
54.5%3 months
116.1%6 months
89.8%-
-
0.63
0.49
0.27
-4.68
1.36
-
-11.51M
14.94M
14.94M
-
-86.23
-
-7.50
-64.04
0.72
0.66
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.20
Range1M
0.23
Range3M
0.58
Rel. volume
0.46
Price X volume
69.97K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.244 | 15.97M | 0.16% | n/a | 118.63% |
Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1368 | 15.04M | 6.79% | n/a | 21.43% |
Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.47 | 14.99M | -2.63% | n/a | 2.12% |
Cingulate Inc. Common Stock | CING | Biotechnology | 4.92 | 14.98M | 7.19% | n/a | 10.72% |
Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
Evogene Ltd | EVGN | Biotechnology | 2.58 | 14.44M | 7.50% | n/a | 26.41% |
IMNN | IMNN | Biotechnology | 0.9925 | 14.29M | 0.71% | n/a | 37.13% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.54 | 14.17M | -3.79% | n/a | 837.11% |
Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.68 | 0.53 | Cheaper |
Ent. to Revenue | 1.36 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.63 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 116.09 | 72.80 | Riskier |
Debt to Equity | 0.49 | -1.23 | Expensive |
Debt to Assets | 0.27 | 0.25 | Par |
Market Cap | 14.94M | 3.66B | Emerging |